MicroPort CardioFlow Medtech Corporation
微創心通醫療科技有限公司

04 FEB 2021

MicroPort CardioFlow Medtech Corporation (the “Company”) is a medical device company in China focusing on the research, development and commercialization of innovative transcatheter and surgical solutions for valvular heart diseases. The Company’s mission is to improve the lives of valvular heart disease patients by providing optimal and affordable medical solutions through continuous innovation. The Company’s self-developed first-generation transcatheter aortic valve implantation (“TAVI”) product, VitaFlow™, was approved by the NMPA in July 2019 and subsequently commercialized in China in August 2019. According to Frost & Sullivan, VitaFlow™ is the first commercialized TAVI product utilizing bovine pericardium as valve tissue in China.

微創心通醫療科技有限公司（「公司」）是一家中國醫療器械企業，專注於心臟瓣膜疾病領域創新的經導管及手術解決方案的研發和商業化。公司的使命是持續創新，為心臟瓣膜疾病患者提供能改善其生活質量的最佳普惠醫療解決方案。公司自主研發的第一代經導管主動脈瓣植入（「TAVI」）產品VitaFlow™，於2019年7月獲國家藥監局審批並隨後於2019年8月在中國進行商業化。根據弗若斯特沙利文的資料，VitaFlow™是首款使用牛心包作為瓣膜組織的商業化TAVI產品。